Amryt Pharma

Amryt Pharma focuses on the developing and delivering new treatments to help improve the lives of patients with rare and orphan diseases. Read more

2 Followers on Owler
2 Followers on Owler
2 Followers on Owler
2 Followers on Owler

Amryt Pharma

Amryt Pharma focuses on the developing and delivering new treatments to help improve the lives of patients with rare and orphan diseases. Read more

Joseph Wiley's photo - Co-Founder & CEO of Amryt Pharma

Co-Founder & CEO

Joseph Wiley

CEO Approval Rating

82/100

Founded:

2015

Status:

PublicIndependent CompanyLondon Stock ExchangeAMYT

AMRYT PHARMA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

AOP Orphan is Amryt Pharma's #1 competitor. AOP Orphan's headquarters is in Vienna, Vienna, and was founded in 1996. AOP Orphan competes in the industry. AOP Orphan generates 63% of Amryt Pharma's revenue.

Auspex Pharmaceuticals is one of Amryt Pharma's top rivals. Auspex Pharmaceuticals was founded in La Jolla, California} in 2001. Like Amryt Pharma, Auspex Pharmaceuticals also works within the Pharmaceuticals sector. Compared to Amryt Pharma, Auspex Pharmaceuticals generates $95M less revenue.

aTyr Pharma is one of Amryt Pharma's top competitors. aTyr Pharma is a Public company that was founded in 2005 in San Diego, California. aTyr Pharma operates in the Biotechnology industry. Compared to Amryt Pharma, aTyr Pharma has 130 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Amryt Pharma?

Amryt Pharma Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$100M

Amryt Pharma's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 44.3M. Over the last two quarters, Amryt Pharma's revenue has grown by 3.6%. Specifically, in Q2 2020's revenue was $46.2M; in Q1 2020, it was $44.6M.

Amryt Pharma Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Aegerion Pharmaceuticals, Inc.

May 2019

Source »
undisclosed
Aegerion develops and commercializes novel therapies for patients with rare diseases.

These are all the companies that Amryt Pharma has acquired. Amryt Pharma's latest acquisition was Aegerion Pharmaceuticals, Inc. in May 2019. Aegerion develops and commercializes novel therapies for patients with rare diseases.

Amryt Pharma Funding History

$21.2M$30.8M

Since Amryt Pharma was founded in 2015, it has participated in 2 rounds of funding. In total Amryt Pharma has raised $30.8M. Amryt Pharma's last funding round was on Dec 2018 for a total of $9.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Dec 2018
$9.6M
-
Debt
Dec 2016
$21.2M

Since Amryt Pharma was founded in 2015, it has participated in 2 rounds of funding. In total Amryt Pharma has raised $30.8M. Amryt Pharma's last funding round was on Dec 2018 for a total of $9.6M

Amryt Pharma Investments

No recent investments found related to Amryt Pharma

These are all the companies that Amryt Pharma has invested in. Amryt Pharma's latest investment was Aegerion Pharmaceuticals, Inc. in May 2019. Aegerion develops and commercializes novel therapies for patients with rare diseases.

Amryt Pharma News

February 4, 2021Sharecast

Amryt signs multi-regional distribution deals with Medison

Commercial-stage biopharmaceuticals company Amryt Pharma announced the signing of multi-regional dist... See more »
January 20, 2021Sharecast

NICE approves Amryt's Myalepta for reimbursement in England and Wales

Commercial-stage biopharmaceutical company Amryt Pharma announced on Wednesday that the National Inst... See more »
January 20, 2021Pharmafile

NICE approves lipid disorder drug Myalepta for NHS use

NICE has approved Amryt's rare lipid disorder drug Myalepta (metreleptin), currently the only leptin ... See more »
January 6, 2021FE Investegate

Amryt to present at H.C Wainwright Conference

7:00 AM: (AMYT) Amryt to present at H.C Wainwright Conference... See more »
December 23, 2020MarketScreener

Amryt Granted Orphan Drug Designation by the FDA for AP103

(marketscreener.com) Amryt Granted Orphan Drug Designation by the FDA for AP103 DUBLIN, Ireland, and ... See more »
December 23, 2020Proactive Investors

Amryt Pharma treatment awarded US orphan status for fragile skin condition

AP103 offers a potential treatment for patients with DEB, a subset of Epidermolysis Bullosa (EB)... See more »

Amryt Pharma Press Releases

September 25, 2019GlobeNewswire

Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therape... See more »
March 29, 2018MarketersMedia

Snapshot of the Global Therapeutic Landscape of Acromegaly to Deliver by Research Available at The Market Reports

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipe... See more »

Social Media

Amryt Pharma Headquarters

1 Adam Street Ivybridge House

London, EnglandWC2N 6LE

353-644-0007

Driving Directions »

Trending Companies

Amryt Pharma Summary

ABOUT

Overview

Amryt Pharma focuses on the developing and delivering new treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma was founded in 2015. Amryt Pharma's headquarters is located in London, England, GB WC2N 6LE. It has ...

CEO

Amryt Pharma's Co-Founder & CEO, Joseph Wiley, currently has an approval rating of 82%. Amryt Pharma's primary competitors are AOP Orphan, Auspex Pharmaceuticals & aTyr Pharma.

Website

amrytpharma.com

Frequently Asked Questions about Amryt Pharma

  1. When was Amryt Pharma founded?

    Amryt Pharma was founded in 2015
  2. Who is Amryt Pharma's CEO?

    Amryt Pharma's CEO is Joseph Wiley
  3. How much revenue does Amryt Pharma generate?

    Amryt Pharma generates $100M in revenue
  4. How much funding does Amryt Pharma have?

    Amryt Pharma has historically raised $30.8M in funding
  1. Where is Amryt Pharma's headquarters?

    Amryt Pharma's headquarters is in London England, GB
  2. How many employees does Amryt Pharma have?

    Amryt Pharma has 169 employees
  3. What sector does Amryt Pharma operate in?

    Amryt Pharma is in Pharmaceuticals, Biotechnology
  4. Who are Amryt Pharma's competitors?

    Amryt Pharma's top competitors are AOP Orphan, Auspex Pharmaceuticals, aTyr Pharma